Greenland Mines Ltd notified the SEC it could not timely file its Quarterly Report on Form 10-Q for the period ended March 31, 2026. The company cites the time required to complete final revisions to the report and to coordinate preparation and inclusion of exhibits.
Greenland Mines Ltd filed a report describing an investor presentation and press release on its Skaergaard critical minerals project in Southeast Greenland. The materials highlight a large gold, palladium and platinum Mineral Resource and outline upcoming field and metallurgical programs.
The Skaergaard Project hosts 159 Mt of Indicated and 205 Mt of Inferred Mineral Resources with a gross in‑situ contained metal value of about $68 billion at February 2026 metal prices, based on NI 43‑101 estimates. These total 11.4 Moz PdEq Indicated and 14.1 Moz PdEq Inferred.
The company plans a 2026 campaign including resource expansion drilling, geotechnical work, environmental baseline studies and a 30–50 tonne bulk sample to support processing flowsheet development with GTK Mintec in Finland. It is also evaluating vanadium, gallium, iron and titanium by‑product potential and an Iceland‑based processing concept within a proposed North Atlantic Critical Minerals Corridor.
Greenland Mines Ltd reported that its Board of Directors appointed Jason D. Sawyer as a director, effective immediately, to fill a vacancy. He will serve until the next annual meeting of stockholders and until a successor is elected and qualified.
Mr. Sawyer, age 54, is a 33-year veteran of the alternative investment industry and General Manager of Access Alternative Group S.A. Over his career, he and firms where he was a principal have raised more than $5 billion in alternative assets and deployed more than US$300 million in early and growth-stage investments.
He has no family relationships with the company’s directors or executive officers, is not involved in related-party transactions requiring disclosure, and has not entered into any agreement with the company regarding his appointment. He currently holds executive and board roles at several other public companies.
Greenland Mines Ltd (GRML), formerly Klotho Neurosciences, described its medicine-development business and reported completing the acquisition of Greenland Mines Corp. in March 2026, adding critical- and precious-minerals development and mining.
Its medicine programs include licensed generic drugs and biosimilar biologics, plus a patented Klotho gene-therapy platform. Lead candidates KLTO-101 for Alzheimer’s disease and KLTO-202 for ALS are preclinical; Greenland Mines states it has not submitted an IND application for any gene therapy.
The company says additional funding from equity and/or debt securities is needed to execute development plans and continue operations. Without it, substantial doubt exists about its ability to continue as a going concern for twelve months from the financial statements’ date. Management found disclosure controls and internal controls over financial reporting ineffective as of December 31, 2025, citing inadequate accounting resources, lack of segregation of duties and a need for a stronger control environment. After additional analyses and procedures, management said the 2025 financial statements were fairly stated in all material respects under GAAP.
Greenland Mines Ltd has received an additional 180-day period, through September 14, 2026, to regain compliance with Nasdaq’s minimum $1.00 per share bid price requirement. The company must achieve a closing bid of at least $1.00 for 10 consecutive business days within this window or its common stock will be subject to delisting from Nasdaq.
The extension reflects that Greenland Mines currently meets all other Nasdaq listing standards, including market value of publicly held shares. The company highlights two divisions: Natural Resources, anchored by the Skaergaard Project in Southeast Greenland with a 2022 NI 43-101 Indicated and Inferred Mineral Resource of 25.4 Moz PdEq and 23.5 Moz AuEq, and Cell and Gene Therapy, including the KLTO-202 program for ALS.